#Vemlidy

Most study participants achieved viral suppression with minimal changes in kidney function or bone density.

Most people who stopped long-term nucleoside/nucleotide analogs did not need to restart treatment.

The antiviral treatment is safe and effective for pediatric patients ages 12 and up.

Antiretroviral therapy for HIV, also effective against HBV, lowers the risk of developing chronic hepatitis.

People living with both viruses remain at risk for hepatocellular carcinoma despite antiviral therapy.

Two different studies found that Vemlidy was safe and effective for pregnant women and their infants.

People who switched showed improvement in markers of kidney and bone health but also rise in lipid levels.

People treated with Viread, Vemlidy or Baraclude are less likely to develop this malignancy.

Some study participants experienced hepatitis B surface antigen loss, considered a functional cure.

Swiss researchers analyzed shifts in kidney function among those switching from the old form of the HIV medication to the new one.

People who added ABI-H0731 saw greater viral load reductions than those who used nucleoside/nucleotide analogues alone.

A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco

Among those who switched their hep B treatment, Vemlidy may also be tied to a higher chance of ALT liver enzyme normalization.

Gilead Sciences has released multiple combo tablets that contain the updated tenofovir, which is linked to improved bone and kidney makers.